Core Viewpoint - The court ruling on the securities fraud case involving Longli Bio and its underwriter Guolian Minsheng Securities has resulted in significant compensation for investors, highlighting the accountability of both the company and its intermediaries in financial misconduct [1][2][3] Group 1: Court Ruling and Compensation - The Jinan Intermediate People's Court ruled that 1,618 investors are entitled to over 275 million yuan in compensation due to Longli Bio's fraudulent financial practices [1] - Longli Bio's actual controller, Cheng Shaobo, is held jointly liable for the compensation, while Guolian Minsheng Securities and Lixin Accounting Firm are responsible for 5% and 30% of the compensation, respectively [1][2] - The total compensation includes 274 million yuan in investment loss, 809,000 yuan in legal fees, and 80,700 yuan in notification fees [2] Group 2: Background of Longli Bio - Longli Bio was a prominent biomass energy company listed on the Shenzhen Stock Exchange, but it faced severe financial issues leading to its delisting in 2020 [1] - The company engaged in systematic profit inflation from 2015 to mid-2017, which concealed operational losses [1] - The China Securities Regulatory Commission (CSRC) found that Longli Bio's financial fraud lasted for several years and involved substantial amounts, resulting in fines for both the company and its key personnel [1] Group 3: Legal and Regulatory Implications - The ruling emphasizes the strict regulatory environment targeting financial fraud, particularly actions led by actual controllers like Cheng Shaobo [3] - The differentiation in liability between the underwriting and auditing firms reflects the judicial system's expectations of intermediaries' roles in the capital market [3] - As the comprehensive registration system reform progresses, the responsibilities of intermediary institutions are expected to increase [3]

Core Viewpoint - The first-instance judgment of the Dragon Power Bio case has been announced, with 1,618 investors entitled to compensation for investment losses totaling 274 million yuan and legal fees of 809,000 yuan [3][5]. Group 1: Case Details - The Jinan Intermediate People's Court ruled that the total investment loss claims against Dragon Power Bio amount to 274 million yuan, with additional legal fee claims of 809,000 yuan [5]. - Defendant Cheng Shaobo is jointly liable for the debts owed to the investors, while other defendants share liability within certain proportions [5]. - Two intermediary institutions are included in the list of defendants, with Guolian Minsheng Securities bearing 5% of the losses and Lixin Accounting Firm responsible for 30% of the losses [5]. Group 2: Company Background - Dragon Power Bio, established in June 2001 and listed in 2011, was once known as the "first stock of biofuels" due to its unique circular economy model [7]. - The company utilizes corn and corn cobs as raw materials to produce functional sugars, starch, and other products, while recycling waste to create second-generation fuel ethanol [7]. - The company faced mandatory delisting from the Shenzhen Stock Exchange on May 22, 2020, due to three consecutive years of losses, with total losses amounting to 7.1 billion yuan from 2017 to 2019 [7][8]. Group 3: Financial Misconduct - From 2015 to 2017, Dragon Power Bio engaged in financial misconduct, including altering financial data and forging accounting documents, leading to inflated assets and profits [8]. - Specific instances of financial manipulation include a nearly 500 million yuan asset inflation and a profit increase of approximately 140 million yuan for the year 2015 [8]. - The China Securities Regulatory Commission (CSRC) has highlighted this case as a typical example of financial fraud, emphasizing the need for strict adherence to accounting standards and disclosure obligations [9].

Core Viewpoint - The court ruling regarding the securities fraud liability dispute of Shandong Longli Biological Technology Co., Ltd. has been announced after five years of delisting, with 1,618 investors involved in the lawsuit claiming a total of 274 million yuan in investment loss and additional legal fees [2][5]. Summary by Sections Company Background - Longli Biological was listed on the Shenzhen Stock Exchange on July 28, 2011, under the stock code 002604, and was known as the "first stock of biofuels" [4]. - The company faced severe issues with systematic fraud, leading to its delisting from the stock exchange on July 1, 2020, after being labeled as "ST Longli" due to risk warnings [4]. Legal Proceedings - The lawsuit involved 1,628 investors who sought compensation for investment losses, commissions, and stamp duty losses from Longli Biological and associated parties, including its former chairman Cheng Shaobo and intermediary firms [5]. - The Jinan Intermediate People's Court ruled that the 1,618 plaintiffs are entitled to a total of 274 million yuan in investment loss claims and 809,000 yuan in legal fees, with additional notification fees for five representative plaintiffs [2][5]. Liability and Compensation - Cheng Shaobo is held jointly liable for the debts owed to the plaintiffs, while other defendants share liability within specified limits [2][5]. - The intermediary firm Guolian Minsheng Securities is responsible for 5% of the plaintiffs' losses, while Lixin Accounting Firm is liable for 30% [2][5]. Implications for Intermediaries - The ruling emphasizes the principle of holding primary offenders accountable while also ensuring that intermediaries are appropriately penalized based on their level of responsibility, thus maintaining a balance in liability [9].

Core Viewpoint - The first-instance judgment regarding the securities false statement liability dispute of Shandong Longli Biological Technology Co., Ltd. has been issued after five years of delisting, with 1,618 investors participating in the lawsuit and claiming a total of 274 million yuan in investment loss [1][2][3]. Group 1: Legal Proceedings and Financial Implications - The Jinan Intermediate People's Court ruled that the 1,618 plaintiffs are entitled to a total investment loss claim of 274 million yuan and legal fees of 809,000 yuan, with five representative plaintiffs also entitled to notification fees of 80,600 yuan [1][3]. - Defendant Cheng Shaobo is jointly liable for the debts owed to the plaintiffs, while other defendants bear joint liability within a certain proportion [1][3]. - Guolian Minsheng Securities is liable for 5% of the plaintiffs' losses, while Lixin Accounting Firm is liable for 30% of the plaintiffs' losses [1][3]. Group 2: Company Background and Historical Context - Longli Biological was listed on the Shenzhen Stock Exchange on July 28, 2011, under the stock code 002604, and was known as the "first stock of biofuels" [2]. - The company was placed under risk warning on January 19, 2018, and was officially delisted on July 1, 2020, transitioning to the National Equities Exchange and Quotations [2]. - The China Securities Regulatory Commission previously identified Longli Biological for significant fraud, leading to penalties including a fine of 600,000 yuan for the company and 1.5 million yuan for Cheng Shaobo [2]. Group 3: Future Considerations and Company Status - Following the judgment, the parties involved may appeal to the Shandong High People's Court, indicating that the final outcome remains uncertain [4]. - Guolian Minsheng Securities stated that the lawsuit will not have a significant adverse impact on the company's current or future profits, as the financial status of the company remains stable and operations are normal [4].

Core Viewpoint - The court ruling on the securities fraud liability dispute involving Shandong Longli Biological Technology Co., Ltd. (Longli Bio) has concluded after five years post-delisting, with 1,618 investors claiming a total of 274 million yuan in investment loss and additional legal fees [1][2][3]. Group 1: Court Ruling and Financial Implications - The Jinan Intermediate People's Court ruled that the 1,618 plaintiffs are entitled to a total of 274 million yuan in investment loss claims and 809,000 yuan in legal fees, with five representative plaintiffs also entitled to 80,600 yuan in notification fees [1][3]. - Defendant Cheng Shaobo is jointly liable for the debts owed to the plaintiffs, while other defendants will bear joint liability within a certain proportion [1][3]. - Guolian Minsheng Securities is liable for 5% of the plaintiffs' losses, while Lixin Accounting Firm is liable for 30% of the losses [1][3]. Group 2: Background and Context - Longli Bio was listed on the Shenzhen Stock Exchange on July 28, 2011, and was once known as the "first stock of biofuels" [2]. - The company was placed under risk warning in January 2018 and was officially delisted in July 2020 due to significant fraudulent activities, including profit inflation from 2015 to mid-2017 [2][3]. - The China Securities Regulatory Commission (CSRC) previously identified Longli Bio for systematic fraud, resulting in fines totaling 3.38 million yuan against 18 responsible parties [2]. Group 3: Legal Proceedings and Future Outlook - The collective lawsuit initiated by over 1,600 investors against Longli Bio and associated parties has taken three years to reach a verdict [3]. - Following the ruling, Guolian Minsheng announced the potential for appeals, indicating that the final judgment remains uncertain [4]. - The company maintains a stable financial status, asserting that the lawsuit's financial implications will not significantly affect its current or future profits [4].

Core Viewpoint - After five years of delisting, Shandong Longli Biological Technology Co., Ltd. has been ordered to compensate 1,618 investors a total of over 270 million yuan due to securities false statements [1] Group 1: Legal Proceedings - The Jinan Intermediate Court has ruled that the 1,618 plaintiffs collectively hold a claim for investment loss of 274 million yuan and legal fees of 809,000 yuan against Longli Biological [1] - Five representative plaintiffs also have a claim for notification fees amounting to 80,600 yuan [1] Group 2: Liability of Defendants - Defendants Cheng Shaobo and others are jointly liable for the debts of Longli Biological [1] - Guolian Minsheng Securities Co., Ltd. is responsible for 5% of the plaintiffs' total losses as part of the joint compensation [1] - Lixin Certified Public Accountants is liable for 30% of the plaintiffs' total losses in the joint compensation [1]

根据济南中院判决，1618名原告共计对龙力生物享有投资差额损失债权2.74亿元、律师费债权80.9万 元；五名原告代表人还对龙力生物享有通知费债权8.06万元。被告程少博等人对龙力生物的债务承担连 带清偿责任。中介机构方面，国联民生证券承销保荐有限公司在原告各项损失5%的范围内承担连带赔 偿责任，立信会计师事务所在原告各项损失30%的范围内承担连带赔偿责任。 （原标题：独家|龙力生物证券虚假陈述责任纠纷判决结果出炉：1618名投资者获赔超2.7亿元） 人民财讯8月26日电，券中社记者独家获悉，退市五年后，山东龙力生物科技股份有限公司（简称"龙力 生物"）证券虚假陈述责任纠纷判决结果出炉。此前，法院启动普通代表人诉讼程序，共计1618名投资 者加入诉讼成为原告。 ...

Core Viewpoint - Luckin Coffee's expansion into the U.S. market has been marred by compliance issues, highlighting the challenges faced by Chinese companies in adapting to foreign regulations and the importance of maintaining a trustworthy compliance framework [5][10][25]. Group 1: Company Overview - Luckin Coffee achieved a "lightning listing" on NASDAQ in just 18 months, but took over six years to establish a presence in the U.S. market [7]. - The company opened two stores in Manhattan on June 30, strategically located near New York University and the Empire State Building, both within a hundred meters of Starbucks locations [7]. Group 2: Pricing Strategy - The introduction of promotional pricing, such as $0.99 for new customer coupons and $1.99 for discounted drinks, generated significant consumer interest and social media buzz [8]. Group 3: Compliance Issues - Luckin's refusal to accept cash payments at its New York locations violated New York City's "no cash" law, which aims to protect low-income and vulnerable populations [10][13]. - The company's operational model, which worked in China, faced significant challenges in the U.S. due to regulatory differences [10]. Group 4: Audit and Compliance Challenges - Luckin Coffee's compliance issues stem from a history of financial fraud, which led to its exit from the NASDAQ main board and ongoing scrutiny from U.S. regulators [16][25]. - The company has changed auditors three times in five years, indicating instability and ongoing compliance challenges [18][24]. - Recent penalties against its auditors, such as the permanent revocation of registration for Marcum Bernstein & Pinchuk LLP, reflect the stringent compliance expectations in the U.S. [19][20]. Group 5: Financial Performance - Despite impressive revenue growth from 2021 to 2024, with increases of 97.5%, 66.9%, 87.3%, and 38.4% respectively, the U.S. capital market prioritizes compliance and trustworthiness over mere financial performance [25].

Core Viewpoint - The article discusses the increasing trend of listed companies suing accounting firms over dissatisfaction with audit services, highlighting the structural weaknesses faced by accounting firms in their relationships with these companies [1][5]. Group 1: Frequency of Lawsuits - Since the beginning of 2024, at least six listed companies have filed lawsuits against accounting firms due to dissatisfaction with their audit services [1]. - *ST Xinchao has sued Lixin Accounting Firm for 3.501 million yuan, claiming negligence in their audit work [2]. - Other companies, including *ST Hengli and Gongzhi Tui, have also initiated legal actions against various accounting firms for similar reasons [4][6]. Group 2: Structural Weakness of Accounting Firms - Experts indicate that the lawsuits reflect a fundamental weakness in the position of accounting firms when dealing with listed companies, suggesting a need for reforms to enhance audit independence [1][5]. - The relationship between accounting firms and listed companies is characterized by a conflict of interest, where firms may feel pressured to compromise their independence due to their reliance on these companies for fees [7][8]. Group 3: Suggestions for Improvement - Experts propose several reforms to strengthen the independence of accounting firms, including trialing third-party payment for audit services and implementing mandatory rotation of accounting firms [9][10]. - The introduction of a three-dimensional system combining economic separation, functional isolation, and process control is suggested to enhance audit independence [11].

Core Viewpoint - *ST Xinchao (600777.SH) has filed a rare lawsuit against its auditing firm, Lixin Certified Public Accountants, seeking over 3 million yuan in damages and the retraction of an audit report that expressed an inability to provide an opinion [1][3]. Group 1: Audit Dispute - The lawsuit centers on the audit of overseas oil and gas assets, with Lixin stating it could not obtain sufficient audit evidence, while *ST Xinchao claims it provided complete information [1][8]. - The company is requesting the court to annul Lixin's audit report and internal control audit report, and to refund over 3.5 million yuan in audit fees, along with 300,000 yuan in legal fees, totaling 3.801 million yuan [3][8]. - The audit reports raised concerns regarding the management of oil and gas assets, employee compensation, and royalty calculations, with Lixin unable to verify the accuracy of the reported figures [8][10]. Group 2: Financial Reporting Challenges - The 2024 annual report faced significant delays, attributed to the departure of multiple accounting firms and the need for extensive documentation [2][6]. - The report was eventually disclosed in early July after Lixin took over the audit on March 20, following the resignation of previous auditors due to internal control disagreements [6][7]. Group 3: Control Rights Controversy - *ST Xinchao is currently embroiled in a power struggle, with six minority shareholders planning to convene an extraordinary general meeting to reorganize the management [2][11]. - The management is under pressure to demonstrate its competence in internal controls amid the ongoing audit dispute, which has implications for the company's survival [11][12]. - The company has faced multiple attempts by shareholders to call for a meeting, with disputes over the legality of the self-convened meeting process [12][14]. Group 4: Shareholder Dynamics - In April, a new major shareholder, Yitai B, acquired 34.07 billion shares of *ST Xinchao, representing 50.1% of the total shares, intensifying the control rights conflict [17].